A study highlighted the accuracy of three leading continuous glucose monitors (CGM), including systems from Abbott and Dexcom.
The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.
Oncology studies present unique challenges when it comes to participant treatment, resupply, and study management.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback